Want to see INBX full AI Analyst Report?
Inhibrx Biosciences Inc (INBX) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pembrolizumab, Inbrx-106 | Head And Neck Squamous Cell Carcinoma (Hnscc) | phase2AndPhase3 | Recruiting | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC | Feb 22, 2024 | ― |
| Inbrx-109 | Conventional Chondrosarcoma | Phase II | Recruiting | Study of INBRX-109 in Conventional Chondrosarcoma | Jun 14, 2021 | ― |
| Inbrx-106 - Hexavalent Ox40 Agonist Antibody, Pembrolizumab 200 Mg, Pembrolizumab 400 Mg, Carboplatin Auc-5, Carboplatin Auc-6, Pemetrexed 500 Mg/M2, Cisplatin 75Mg/M2, Paclitaxel 200Mg/M2, Nab Paclitaxel 100Mg/M2 | Melanoma, Urothelial Carcinoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Solid Tumor, Gastric Cancer, Head And Neck Cancer | phase1AndPhase2 | Recruiting | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Dec 11, 2019 | ― |
| Irinotecan, Pemetrexed, Carboplatin, Cisplatin, Temozolomide, 5-Fluorouracil, Inbrx-109 | Colorectal Adenocarcinoma, Ewing Sarcoma | Phase I | Recruiting | Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Oct 11, 2018 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pembrolizumab, Inbrx-106 | phase2AndPhase3 | Head And Neck Squamous Cell Carcinoma (Hnscc) | Recruiting | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC | Feb 22, 2024 | ― |
| Inbrx-109 | Phase II | Conventional Chondrosarcoma | Recruiting | Study of INBRX-109 in Conventional Chondrosarcoma | Jun 14, 2021 | ― |
| Inbrx-106 - Hexavalent Ox40 Agonist Antibody, Pembrolizumab 200 Mg, Pembrolizumab 400 Mg, Carboplatin Auc-5, Carboplatin Auc-6, Pemetrexed 500 Mg/M2, Cisplatin 75Mg/M2, Paclitaxel 200Mg/M2, Nab Paclitaxel 100Mg/M2 | phase1AndPhase2 | Melanoma, Urothelial Carcinoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Solid Tumor, Gastric Cancer, Head And Neck Cancer | Recruiting | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Dec 11, 2019 | ― |
| Irinotecan, Pemetrexed, Carboplatin, Cisplatin, Temozolomide, 5-Fluorouracil, Inbrx-109 | Phase I | Colorectal Adenocarcinoma, Ewing Sarcoma | Recruiting | Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Oct 11, 2018 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Inhibrx Biosciences, Inc. (INBX) have in its pipeline
Inhibrx Biosciences Inc INBX is currently developing the following drugs: Pembrolizumab, Inbrx-106, Inbrx-109, Inbrx-106 - Hexavalent Ox40 Agonist Antibody, Pembrolizumab 200 Mg, Pembrolizumab 400 Mg, Carboplatin Auc-5, Carboplatin Auc-6, Pemetrexed 500 Mg/M2, Cisplatin 75Mg/M2, Paclitaxel 200Mg/M2, Nab Paclitaxel 100Mg/M2, Irinotecan, Pemetrexed, Carboplatin, Cisplatin, Temozolomide, 5-Fluorouracil, Inbrx-109. These drug candidates are in various stages of clinical development as the company works toward FDA approval.